Franklin Resources’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.04M Buy
30,407
+6,920
+29% +$209K ﹤0.01% 2259
2026
Q1
$560K Buy
23,487
+1,539
+7% +$42.7K ﹤0.01% 2424
2025
Q4
$608K Buy
21,948
+566
+3% +$14.4K ﹤0.01% 2316
2025
Q3
$519K Buy
21,382
+2,284
+12% +$45.4K ﹤0.01% 2410
2025
Q2
$325K Sell
19,098
-1,475
-7% -$25.7K ﹤0.01% 2530
2025
Q1
$402K Sell
20,573
-780
-4% -$20.4K ﹤0.01% 2352
2024
Q4
$530K Buy
21,353
+6,315
+42% +$161K ﹤0.01% 2260
2024
Q3
$400K Buy
+15,038
New +$389K ﹤0.01% 2374
2022
Q2
Sell
-5,082
Closed -$291K 2374
2022
Q1
$291K Sell
5,082
-1,908
-27% -$125K ﹤0.01% 2023
2021
Q4
$557K Buy
6,990
+183
+3% +$15.7K ﹤0.01% 1869
2021
Q3
$593K Buy
6,807
+3,417
+101% +$343K ﹤0.01% 1821
2021
Q2
$436K Buy
3,390
+818
+32% +$65.2K ﹤0.01% 1636
2021
Q1
$206K Buy
+2,572
New +$245K ﹤0.01% 1808
2020
Q2
Sell
-300,509
Closed -$5.41M 1687
2020
Q1
$5.41M Buy
+300,509
New +$6.53M ﹤0.01% 915

Other funds holding BEAM

Franklin Resources's BEAM Position: Q2 2026 in Review

Franklin Resources increased its Beam Therapeutics (BEAM) stake by 29% in Q2 2026, buying an estimated $209K and bringing the position to 30,407 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2259.

Franklin Resources first reported a position in BEAM in Q1 2020 and has held it in 14 quarters since. The position peaked at $5.41M in Q1 2020. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Franklin Resources held 30,407 shares of Beam Therapeutics worth $1.04M as of Q2 2026.
  • Franklin Resources bought 6,920 Beam Therapeutics shares in Q2 2026, an estimated $209K.
  • Beam Therapeutics made up ﹤0.01% of Franklin Resources's portfolio in Q2 2026, its #2259 holding.
  • Franklin Resources first reported a position in Beam Therapeutics in Q1 2020 and has held it in 14 quarters since.
  • Franklin Resources's Beam Therapeutics position peaked at $5.41M in Q1 2020.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.